Leal Therapeutics develops precision medicines targeting CNS disorders including ALS, Peripheral Neuropathy, Alzheimer's Disease, and Schizophrenia.

Leal Therapeutics

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

WordPress

Global Site Tag

Font Awesome

Director

Brian Kile

Principal Scientist, CNS Biology

Allie Muthukumar

Principal Scientist

Anumeha Shah

CEO and Founder

Asa Abeliovich

Vice President Clinical Development

Lawrence Severt

Thomas Cahill

Xianglin Shi

East Coast Companies (Top 10K)

East Coast Companies With More Than 10 Employees (Top 10K)

Northeastern US Companies With Fewer Than 100 Employees (Top 10K)

Harvard Medical School Alumni Founded Companies

Leal Therapeutics develops novel therapeutics for patients.

Newpath Management

Venture Round - Leal Therapeutics

Seed Round - Leal Therapeutics

Worcester

Massachusetts

United States

North America

Leal Therapeutics: $45 Million Secured To Advance Novel Therapies For Patients With Major Neurodegenerative Disorders

Worcester startup raises $45M for ALS and schizophrenia treatment

Leal Therapeutics Announces $45 Million Financing

Leal Therapeutics raises $45M; SynOx adds to Series B

Leal Therapeutics Raises $45M Financing

With $39M in seed funding, Worcester startup aims to develop ALS, schizophrenia treatments

An antisense oligonucleotide (ASO) targeting SPTLC1 for treating ALS, peripheral neuropathy, and Alzheimer's disease.

A small molecule targeting GLS1 for treating schizophrenia and major depressive disorder (MDD).

An antisense oligonucleotide (ASO) targeting complement for treating Alzheimer's disease, frontotemporal dementia (FTD), and age-related macular degeneration (AMD).

An antisense oligonucleotide (ASO) targeting lipid trafficking for treating Alzheimer's disease and dementia with Lewy bodies.

An antisense oligonucleotide (ASO) targeting glutamate NMDAR for treating refractory epilepsy and treatment-resistant depression (TRD).

Bangladesh

Asia

Mexico

Leal Therapeutics is developing precision medicines for central nervous system (CNS) disorders, focusing on therapies for conditions such as ALS, schizophrenia, and Alzheimer’s disease. The company is working on multiple programs, with clinical data expected in 2025.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 24, 2024 7:12 PM	0e4edc44
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 24, 2024 7:12 PM	33ac050e
crunchbase trigger	general	Nov 25, 2024 9:09 AM	24fcb221
crunchbase profile	general	Nov 25, 2024 9:14 AM	a2708e13
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:00 PM	6a3e2339
peers	general	Oct 24, 2024 7:12 PM	50b9f21f
news basic	general	Oct 24, 2024 7:12 PM	2e3d77d0
bundesanzeiger	filings
financials download nd	financials
private financials	financials

LEAL

COM:LEALTX

Leal Therapeutics